Tomita, M.; Yamamoto, M.; Hirayama, K.; Kyo, A.; Misawa, N.; Kinari, G.; Kohno, T.; Honda, S.
One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients. J. Clin. Med. 2024, 13, 4641.
https://doi.org/10.3390/jcm13164641
AMA Style
Tomita M, Yamamoto M, Hirayama K, Kyo A, Misawa N, Kinari G, Kohno T, Honda S.
One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients. Journal of Clinical Medicine. 2024; 13(16):4641.
https://doi.org/10.3390/jcm13164641
Chicago/Turabian Style
Tomita, Mami, Manabu Yamamoto, Kumiko Hirayama, Akika Kyo, Norihiko Misawa, Gen Kinari, Takeya Kohno, and Shigeru Honda.
2024. "One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients" Journal of Clinical Medicine 13, no. 16: 4641.
https://doi.org/10.3390/jcm13164641
APA Style
Tomita, M., Yamamoto, M., Hirayama, K., Kyo, A., Misawa, N., Kinari, G., Kohno, T., & Honda, S.
(2024). One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients. Journal of Clinical Medicine, 13(16), 4641.
https://doi.org/10.3390/jcm13164641